EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer from an International Collaborative Study (DETECTIVE Study): European Urology

TBL Lam; S MacLennan; PPM Willemse; MD Mason; K Plass; R Shepherd; R Baanders; CH Bangma; A Bjartell; A Bossi; E Briers; A Briganti; KT Buddingh; JWF Catto; M Colecchia; BW Cox; MG Cumberbatch; J Davies; NF Davis; M De Santis; P Dell'Oglio; A Deschamps; JF Donaldson; S Egawa; CD Fankhauser; S Fanti; N Fossati; G Gandaglia; S Gillessen; N Grivas; T Gross; JP Grummet; AM Henry; A Ingels; J Irani; M Lardas; M Liew; DW Lin; L Moris; MI Omar; KH Pang; CC Paterson; R Renard-Penna; MJ Ribal; MJ Roobol; M Rouprêt; O Rouvière; G Sancho Pardo; J Richenberg; IG Schoots; JPM Sedelaar; P Stricker; D Tilki; S Vahr Lauridsen; RCN van den Bergh; T Van den Broeck; TH van der Kwast; HG van der Poel; GJLH van Leenders; M Varma; PD Violette; CJD Wallis; T Wiegel; K Wilkinson; F Zattoni; JMO N'Dow; H Van Poppel; P Cornford; N Mottet

doi:10.1016/j.eururo.2019.09.020

EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer from an International Collaborative Study (DETECTIVE Study): European Urology

TBL Lam, S MacLennan, PPM Willemse, MD Mason, K Plass, R Shepherd, R Baanders, CH Bangma, A Bjartell, A Bossi, E Briers, A Briganti, KT Buddingh, JWF Catto, M Colecchia, BW Cox, MG Cumberbatch, J Davies, NF Davis, M De SantisP Dell'Oglio, A Deschamps, JF Donaldson, S Egawa, CD Fankhauser, S Fanti, N Fossati, G Gandaglia, S Gillessen, N Grivas, T Gross, JP Grummet, AM Henry, A Ingels, J Irani, M Lardas, M Liew, DW Lin, L Moris, MI Omar, KH Pang, CC Paterson, R Renard-Penna, MJ Ribal, MJ Roobol, M Rouprêt, O Rouvière, G Sancho Pardo, J Richenberg, IG Schoots, JPM Sedelaar, P Stricker, D Tilki, S Vahr Lauridsen, RCN van den Bergh, T Van den Broeck, TH van der Kwast, HG van der Poel, GJLH van Leenders, M Varma, PD Violette, CJD Wallis, T Wiegel, K Wilkinson, F Zattoni, JMO N'Dow, H Van Poppel, P Cornford, N Mottet

IRCCS Ospedale San Raffaele

Research output: Contribution to journal › Article › peer-review

Abstract

Background: There is uncertainty in deferred active treatment (DAT) programmes, regarding patient selection, follow-up and monitoring, reclassification, and which outcome measures should be prioritised. Objective: To develop consensus statements for all domains of DAT. Design, setting, and participants: A protocol-driven, three phase study was undertaken by the European Association of Urology (EAU)-European Association of Nuclear Medicine (EANM)-European Society for Radiotherapy and Oncology (ESTRO)-European Association of Urology Section of Urological Research (ESUR)-International Society of Geriatric Oncology (SIOG) Prostate Cancer Guideline Panel in conjunction with partner organisations, including the following: (1) a systematic review to describe heterogeneity across all domains; (2) a two-round Delphi survey involving a large, international panel of stakeholders, including healthcare practitioners (HCPs) and patients; and (3) a consensus group meeting attended by stakeholder group representatives. Robust methods regarding what constituted the consensus were strictly followed. Results and limitations: A total of 109 HCPs and 16 patients completed both survey rounds. Of 129 statements in the survey, consensus was achieved in 66 (51%); the rest of the statements were discussed and voted on in the consensus meeting by 32 HCPs and three patients, where consensus was achieved in additional 27 statements (43%). Overall, 93 statements (72%) achieved consensus in the project. Some uncertainties remained regarding clinically important thresholds for disease extent on biopsy in low-risk disease, and the role of multiparametric magnetic resonance imaging in determining disease stage and aggressiveness as a criterion for inclusion and exclusion. Conclusions: Consensus statements and the findings are expected to guide and inform routine clinical practice and research, until higher levels of evidence emerge through prospective comparative studies and clinical trials. Patient summary: We undertook a project aimed at standardising the elements of practice in active surveillance programmes for early localised prostate cancer because currently there is great variation and uncertainty regarding how best to conduct them. The project involved large numbers of healthcare practitioners and patients using a survey and face-to-face meeting, in order to achieve agreement (ie, consensus) regarding best practice, which will provide guidance to clinicians and researchers. © 2019

Original language	English
Pages (from-to)	790-813
Number of pages	24
Journal	European Urology
Volume	76
Issue number	6
DOIs	https://doi.org/10.1016/j.eururo.2019.09.020
Publication status	Published - 2019

Access to Document

10.1016/j.eururo.2019.09.020

http://www.scopus.com/inward/record.url?scp=85072774547&partnerID=8YFLogxK

Fingerprint

Dive into the research topics of 'EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer from an International Collaborative Study (DETECTIVE Study): European Urology'. Together they form a unique fingerprint.

Cite this

Lam, TBL., MacLennan, S., Willemse, PPM., Mason, MD., Plass, K., Shepherd, R., Baanders, R., Bangma, CH., Bjartell, A., Bossi, A., Briers, E., Briganti, A., Buddingh, KT., Catto, JWF., Colecchia, M., Cox, BW., Cumberbatch, MG., Davies, J., Davis, NF., ... Mottet, N. (2019). EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer from an International Collaborative Study (DETECTIVE Study): European Urology. European Urology, 76(6), 790-813. https://doi.org/10.1016/j.eururo.2019.09.020

EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer from an International Collaborative Study (DETECTIVE Study) : European Urology. / Lam, TBL; MacLennan, S; Willemse, PPM et al.

In: European Urology, Vol. 76, No. 6, 2019, p. 790-813.

Research output: Contribution to journal › Article › peer-review

Lam, TBL, MacLennan, S, Willemse, PPM, Mason, MD, Plass, K, Shepherd, R, Baanders, R, Bangma, CH, Bjartell, A, Bossi, A, Briers, E, Briganti, A, Buddingh, KT, Catto, JWF, Colecchia, M, Cox, BW, Cumberbatch, MG, Davies, J, Davis, NF, De Santis, M, Dell'Oglio, P, Deschamps, A, Donaldson, JF, Egawa, S, Fankhauser, CD, Fanti, S, Fossati, N , Gandaglia, G, Gillessen, S, Grivas, N, Gross, T, Grummet, JP, Henry, AM, Ingels, A, Irani, J, Lardas, M, Liew, M, Lin, DW, Moris, L, Omar, MI, Pang, KH, Paterson, CC, Renard-Penna, R, Ribal, MJ, Roobol, MJ, Rouprêt, M, Rouvière, O, Sancho Pardo, G, Richenberg, J, Schoots, IG, Sedelaar, JPM, Stricker, P, Tilki, D, Vahr Lauridsen, S, van den Bergh, RCN, Van den Broeck, T, van der Kwast, TH, van der Poel, HG, van Leenders, GJLH, Varma, M, Violette, PD, Wallis, CJD, Wiegel, T, Wilkinson, K, Zattoni, F, N'Dow, JMO, Van Poppel, H, Cornford, P & Mottet, N 2019, 'EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer from an International Collaborative Study (DETECTIVE Study): European Urology', European Urology, vol. 76, no. 6, pp. 790-813. https://doi.org/10.1016/j.eururo.2019.09.020

Lam TBL, MacLennan S, Willemse PPM, Mason MD, Plass K, Shepherd R et al. EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer from an International Collaborative Study (DETECTIVE Study): European Urology. European Urology. 2019;76(6):790-813. doi: 10.1016/j.eururo.2019.09.020

@article{c8863adfe347465e929e03652aa85bcd,

title = "EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer from an International Collaborative Study (DETECTIVE Study): European Urology",

abstract = "Background: There is uncertainty in deferred active treatment (DAT) programmes, regarding patient selection, follow-up and monitoring, reclassification, and which outcome measures should be prioritised. Objective: To develop consensus statements for all domains of DAT. Design, setting, and participants: A protocol-driven, three phase study was undertaken by the European Association of Urology (EAU)-European Association of Nuclear Medicine (EANM)-European Society for Radiotherapy and Oncology (ESTRO)-European Association of Urology Section of Urological Research (ESUR)-International Society of Geriatric Oncology (SIOG) Prostate Cancer Guideline Panel in conjunction with partner organisations, including the following: (1) a systematic review to describe heterogeneity across all domains; (2) a two-round Delphi survey involving a large, international panel of stakeholders, including healthcare practitioners (HCPs) and patients; and (3) a consensus group meeting attended by stakeholder group representatives. Robust methods regarding what constituted the consensus were strictly followed. Results and limitations: A total of 109 HCPs and 16 patients completed both survey rounds. Of 129 statements in the survey, consensus was achieved in 66 (51%); the rest of the statements were discussed and voted on in the consensus meeting by 32 HCPs and three patients, where consensus was achieved in additional 27 statements (43%). Overall, 93 statements (72%) achieved consensus in the project. Some uncertainties remained regarding clinically important thresholds for disease extent on biopsy in low-risk disease, and the role of multiparametric magnetic resonance imaging in determining disease stage and aggressiveness as a criterion for inclusion and exclusion. Conclusions: Consensus statements and the findings are expected to guide and inform routine clinical practice and research, until higher levels of evidence emerge through prospective comparative studies and clinical trials. Patient summary: We undertook a project aimed at standardising the elements of practice in active surveillance programmes for early localised prostate cancer because currently there is great variation and uncertainty regarding how best to conduct them. The project involved large numbers of healthcare practitioners and patients using a survey and face-to-face meeting, in order to achieve agreement (ie, consensus) regarding best practice, which will provide guidance to clinicians and researchers. {\textcopyright} 2019",

author = "TBL Lam and S MacLennan and PPM Willemse and MD Mason and K Plass and R Shepherd and R Baanders and CH Bangma and A Bjartell and A Bossi and E Briers and A Briganti and KT Buddingh and JWF Catto and M Colecchia and BW Cox and MG Cumberbatch and J Davies and NF Davis and {De Santis}, M and P Dell'Oglio and A Deschamps and JF Donaldson and S Egawa and CD Fankhauser and S Fanti and N Fossati and G Gandaglia and S Gillessen and N Grivas and T Gross and JP Grummet and AM Henry and A Ingels and J Irani and M Lardas and M Liew and DW Lin and L Moris and MI Omar and KH Pang and CC Paterson and R Renard-Penna and MJ Ribal and MJ Roobol and M Roupr{\^e}t and O Rouvi{\`e}re and {Sancho Pardo}, G and J Richenberg and IG Schoots and JPM Sedelaar and P Stricker and D Tilki and {Vahr Lauridsen}, S and {van den Bergh}, RCN and {Van den Broeck}, T and {van der Kwast}, TH and {van der Poel}, HG and {van Leenders}, GJLH and M Varma and PD Violette and CJD Wallis and T Wiegel and K Wilkinson and F Zattoni and JMO N'Dow and {Van Poppel}, H and P Cornford and N Mottet",

year = "2019",

doi = "10.1016/j.eururo.2019.09.020",

language = "English",

volume = "76",

pages = "790--813",

journal = "European Urology",

issn = "0302-2838",

publisher = "Elsevier B.V.",

number = "6",

}

TY - JOUR

T1 - EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer from an International Collaborative Study (DETECTIVE Study)

T2 - European Urology

AU - Lam, TBL

AU - MacLennan, S

AU - Willemse, PPM

AU - Mason, MD

AU - Plass, K

AU - Shepherd, R

AU - Baanders, R

AU - Bangma, CH

AU - Bjartell, A

AU - Bossi, A

AU - Briers, E

AU - Briganti, A

AU - Buddingh, KT

AU - Catto, JWF

AU - Colecchia, M

AU - Cox, BW

AU - Cumberbatch, MG

AU - Davies, J

AU - Davis, NF

AU - De Santis, M

AU - Dell'Oglio, P

AU - Deschamps, A

AU - Donaldson, JF

AU - Egawa, S

AU - Fankhauser, CD

AU - Fanti, S

AU - Fossati, N

AU - Gandaglia, G

AU - Gillessen, S

AU - Grivas, N

AU - Gross, T

AU - Grummet, JP

AU - Henry, AM

AU - Ingels, A

AU - Irani, J

AU - Lardas, M

AU - Liew, M

AU - Lin, DW

AU - Moris, L

AU - Omar, MI

AU - Pang, KH

AU - Paterson, CC

AU - Renard-Penna, R

AU - Ribal, MJ

AU - Roobol, MJ

AU - Rouprêt, M

AU - Rouvière, O

AU - Sancho Pardo, G

AU - Richenberg, J

AU - Schoots, IG

AU - Sedelaar, JPM

AU - Stricker, P

AU - Tilki, D

AU - Vahr Lauridsen, S

AU - van den Bergh, RCN

AU - Van den Broeck, T

AU - van der Kwast, TH

AU - van der Poel, HG

AU - van Leenders, GJLH

AU - Varma, M

AU - Violette, PD

AU - Wallis, CJD

AU - Wiegel, T

AU - Wilkinson, K

AU - Zattoni, F

AU - N'Dow, JMO

AU - Van Poppel, H

AU - Cornford, P

AU - Mottet, N

PY - 2019

Y1 - 2019

N2 - Background: There is uncertainty in deferred active treatment (DAT) programmes, regarding patient selection, follow-up and monitoring, reclassification, and which outcome measures should be prioritised. Objective: To develop consensus statements for all domains of DAT. Design, setting, and participants: A protocol-driven, three phase study was undertaken by the European Association of Urology (EAU)-European Association of Nuclear Medicine (EANM)-European Society for Radiotherapy and Oncology (ESTRO)-European Association of Urology Section of Urological Research (ESUR)-International Society of Geriatric Oncology (SIOG) Prostate Cancer Guideline Panel in conjunction with partner organisations, including the following: (1) a systematic review to describe heterogeneity across all domains; (2) a two-round Delphi survey involving a large, international panel of stakeholders, including healthcare practitioners (HCPs) and patients; and (3) a consensus group meeting attended by stakeholder group representatives. Robust methods regarding what constituted the consensus were strictly followed. Results and limitations: A total of 109 HCPs and 16 patients completed both survey rounds. Of 129 statements in the survey, consensus was achieved in 66 (51%); the rest of the statements were discussed and voted on in the consensus meeting by 32 HCPs and three patients, where consensus was achieved in additional 27 statements (43%). Overall, 93 statements (72%) achieved consensus in the project. Some uncertainties remained regarding clinically important thresholds for disease extent on biopsy in low-risk disease, and the role of multiparametric magnetic resonance imaging in determining disease stage and aggressiveness as a criterion for inclusion and exclusion. Conclusions: Consensus statements and the findings are expected to guide and inform routine clinical practice and research, until higher levels of evidence emerge through prospective comparative studies and clinical trials. Patient summary: We undertook a project aimed at standardising the elements of practice in active surveillance programmes for early localised prostate cancer because currently there is great variation and uncertainty regarding how best to conduct them. The project involved large numbers of healthcare practitioners and patients using a survey and face-to-face meeting, in order to achieve agreement (ie, consensus) regarding best practice, which will provide guidance to clinicians and researchers. © 2019

AB - Background: There is uncertainty in deferred active treatment (DAT) programmes, regarding patient selection, follow-up and monitoring, reclassification, and which outcome measures should be prioritised. Objective: To develop consensus statements for all domains of DAT. Design, setting, and participants: A protocol-driven, three phase study was undertaken by the European Association of Urology (EAU)-European Association of Nuclear Medicine (EANM)-European Society for Radiotherapy and Oncology (ESTRO)-European Association of Urology Section of Urological Research (ESUR)-International Society of Geriatric Oncology (SIOG) Prostate Cancer Guideline Panel in conjunction with partner organisations, including the following: (1) a systematic review to describe heterogeneity across all domains; (2) a two-round Delphi survey involving a large, international panel of stakeholders, including healthcare practitioners (HCPs) and patients; and (3) a consensus group meeting attended by stakeholder group representatives. Robust methods regarding what constituted the consensus were strictly followed. Results and limitations: A total of 109 HCPs and 16 patients completed both survey rounds. Of 129 statements in the survey, consensus was achieved in 66 (51%); the rest of the statements were discussed and voted on in the consensus meeting by 32 HCPs and three patients, where consensus was achieved in additional 27 statements (43%). Overall, 93 statements (72%) achieved consensus in the project. Some uncertainties remained regarding clinically important thresholds for disease extent on biopsy in low-risk disease, and the role of multiparametric magnetic resonance imaging in determining disease stage and aggressiveness as a criterion for inclusion and exclusion. Conclusions: Consensus statements and the findings are expected to guide and inform routine clinical practice and research, until higher levels of evidence emerge through prospective comparative studies and clinical trials. Patient summary: We undertook a project aimed at standardising the elements of practice in active surveillance programmes for early localised prostate cancer because currently there is great variation and uncertainty regarding how best to conduct them. The project involved large numbers of healthcare practitioners and patients using a survey and face-to-face meeting, in order to achieve agreement (ie, consensus) regarding best practice, which will provide guidance to clinicians and researchers. © 2019

U2 - 10.1016/j.eururo.2019.09.020

DO - 10.1016/j.eururo.2019.09.020

M3 - Article

SN - 0302-2838

VL - 76

SP - 790

EP - 813

JO - European Urology

JF - European Urology

IS - 6

ER -